HOME SEARCH RESOURCES CONTACT
 
 
 
 
  ROBERT A. CANTONE    
Phone 212.969.3235
rcantone@proskauer.com
 
PARTNER
   
Picture of ROBERT A. CANTONE

Press Room

In The News
Big Deals

Press Releases
Proskauer Rose Represents Gray Television in Issuance of $75 Million of Series D Preferred Stock
Proskauer Rose Represents Celgene in Closing of Acquisition of Pharmion for $2.9 Billion
Proskauer Rose Represents Celgene in Agreement to Acquire Pharmion For $2.9 Billion

View all ROBERT A. CANTONE's Press Room Items

New York Office:
1585 Broadway
Fax 212.969.2900

Practice Areas:
Corporate
Director & Officer Liability
Employee Stock Ownership Plans
Executive Compensation
Fiduciary Duty Of Directors
Health Care
Leveraged Buy - Outs
Mergers & Acquisitions
New York Stock Exchange Issues
Securities
International
Israeli Companies
Business Valuations
Fairness Opinions
Institutional Investing & Investment Funds
Initial Public Offerings
Stockholder Rights
Regulatory / S.E.C.
Limited Liability Companies And Partnerships
Public Offerings - Debt
Public Offerings - Equity
Private Placements
Life Sciences
Education:
NEW YORK UNIVERSITY SCHOOL OF LAW, J.D., 1977
COLUMBIA UNIVERSITY, COLUMBIA COLLEGE, B.A., 1974
 
Bar Admission:
05/24/1978 NEW YORK
 
Biography:

Robert represents publicly traded companies and investor-funded private companies as outside corporate counsel. His clients are primarily in the technology sector and include life sciences and telecommunications firms. With his breadth of experience in structuring and negotiating mergers and acquisitions, strategic partnerships and commercial transactions, Robert is a partner to his clients' senior management and boards of directors in identifying and implementing effective means to achieve corporate objectives.

His work also includes financing transactions, including private and public equity financings, unsecured and asset-based credit facilities and other debt arrangements.

In the M&A area, Robert represents acquirors and sellers of entire enterprises and divisions or product lines in diverse transactional settings, including technology licenses, mergers, leveraged buy-outs, management-led buy-outs and going-private transactions. He also counsels clients concerning proxy contests and other corporate control matters.

Robert has broad experience representing companies in the life sciences sector, from their early stages of development to their maturity as publicly held concerns.

Illustrative transactions for life science clients include:

Celgene Corporation

  • $2.9 billion agreement to acquire Pharmion Corporation

  • $1.032 billion public offering of common stock in 2006 underwritten by J.P. Morgan and Merrill Lynch

  • Acquisition of Anthrogenesis Corporation, a stem cell biotherapeutics company

  • Acquisition of exclusive intellectual property rights from EntreMed, Inc.

Andrx Corporation

  • $1.9 billion merger with Watson Pharmaceuticals

Other representations include PLIVA, Inc., Teva Pharmaceutical Industries Ltd., Les Laboratoires Servier, Schein Pharmaceutical, Inc., Emisphere Technologies, Inc., Savient Pharmaceuticals, and Biocraft Laboratories, Inc.

A native New Yorker, Robert is a graduate of New York University School of Law and Columbia College. He is also a member of the New York Biotechnology Association.

 
   
  ^top